home / stock / clls / clls quote
Last: | $2.04 |
---|---|
Change Percent: | 0.0% |
Open: | $2.05 |
Close: | $2.04 |
High: | $2.0896 |
Low: | $1.9384 |
Volume: | 16,805 |
Last Trade Date Time: | 07/05/2024 03:00:00 am |
Quotes are delayed by 15 to 20 minutes.
Last | Open | Close | High | Low | Volume | Date |
---|---|---|---|---|---|---|
$2.04 | $2.05 | $2.04 | $2.0896 | $1.9384 | 16,805 | 07-05-2024 |
$2.05 | $1.97 | $2.05 | $2.0999 | $1.9636 | 44,377 | 07-04-2024 |
$2.05 | $1.97 | $2.05 | $2.0999 | $1.9636 | 44,377 | 07-03-2024 |
$1.9 | $1.89 | $1.9 | $1.9216 | $1.88 | 14,222 | 07-02-2024 |
$1.935 | $1.87 | $1.935 | $1.9599 | $1.85 | 37,536 | 07-01-2024 |
$1.87 | $1.84 | $1.87 | $1.8995 | $1.84 | 36,154 | 06-28-2024 |
$1.86 | $1.84 | $1.86 | $1.89 | $1.82 | 40,362 | 06-27-2024 |
$1.87 | $1.86 | $1.87 | $1.87 | $1.82 | 99,975 | 06-26-2024 |
$1.93 | $1.9 | $1.93 | $1.9304 | $1.86 | 44,701 | 06-25-2024 |
$1.91 | $1.87 | $1.91 | $1.942 | $1.85 | 45,611 | 06-24-2024 |
$1.89 | $1.85 | $1.89 | $1.93 | $1.82 | 205,112 | 06-21-2024 |
$1.964 | $2.01 | $1.964 | $2.01 | $1.91 | 36,561 | 06-20-2024 |
$2.015 | $2.01 | $2.015 | $2.12 | $1.98 | 127,503 | 06-19-2024 |
$2.015 | $2.01 | $2.015 | $2.12 | $1.98 | 127,503 | 06-18-2024 |
$2.14 | $2.16 | $2.14 | $2.16 | $2.11 | 100,514 | 06-17-2024 |
$2.25 | $2.24 | $2.25 | $2.3 | $2.1 | 54,631 | 06-14-2024 |
$2.36 | $2.34 | $2.36 | $2.385 | $2.29 | 46,950 | 06-13-2024 |
$2.42 | $2.48 | $2.42 | $2.48 | $2.375 | 89,986 | 06-12-2024 |
$2.48 | $2.5 | $2.48 | $2.62 | $2.45 | 87,335 | 06-11-2024 |
$2.57 | $2.54 | $2.57 | $2.57 | $2.46 | 77,635 | 06-10-2024 |
News, Short Squeeze, Breakout and More Instantly...
NEW YORK, June 28, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS; Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, held today a shareholders general meeting at 2:30 p.m. CET at the Biopark...
NEW YORK, June 20, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publication of a...
NEW YORK, June 12, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today the publicatio...